Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Pain, Postoperative 2 Pain 2 Multiple Myeloma 2 Carcinoma, Non-Small-Cell Lung 2 Agnosia 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Lymphoma, Follicular 1 Lymphoma 1 Lung Neoplasms 1 Leukemia, Hairy Cell 1 Hematopoietic and Lymphatic System Neoplasm 1 Head and Neck Neoplasms 1 Fallopian Tube Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Carcinoma in Situ 1 Burkitt Lymphoma 1 Breast Neoplasms 1

Interventions

Bevacizumab 35 Paclitaxel 31 Carboplatin 24 pembrolizumab 23 Specimen Handling 21 Magnetic Resonance Spectroscopy 19 Gemcitabine 18 olaparib 16 liposomal doxorubicin 16 Cyclophosphamide 15 fludarabine 12 Topotecan 12 Biopsy 12 niraparib 11 Cisplatin 10 Taxes 8 Nivolumab 8 Immunoglobulin G 8 Fulvestrant 8 Disulfides 8 Doxorubicin 7 aldesleukin 6 Surveys and Questionnaires 6 palbociclib 5 Oxaliplatin 5 Fluorouracil 5 trastuzumab deruxtecan 4 oregovomab 4 mirvetuximab soravtansine 4 X-Rays 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Neoplasms × Acetaminophen × 90 days × Clear all

NCT06824467 2026-05-29

TroFuse-022

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡